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Chronic dopamine receptor activation is implicated in several central nervous system disorders. Although acute activation of Gαi-
coupled D2 dopamine receptors inhibits adenylyl cyclase, persistent activation enhances adenylyl cyclase activity, a phenomenon
called heterologous sensitization. Previous work revealed a requirement for Gαs in D2-induced heterologous sensitization of
AC5. To elucidate the mechanism of Gαs dependency, we expressed Gαs mutants in Gαs-deﬁcient GnasE2−/E2− cells. Neither Gαs-
palmitoylation nor Gαs-Gβγ interactions were required for sensitization of AC5. Moreover, we found that coexpressing βARKct-
CD8 or Sar1(H79G) blocked heterologous sensitization. These studies are consistent with a role for Gαs-AC5 interactions in
sensitization however, Gβγ appears to have an indirect role in heterologous sensitization of AC5, possibly by promoting proper
signalosome assembly.
1.Introduction
Dopamine receptors and dopamine signaling have been im-
plicated in various neurological and psychiatric disorders in-
cluding Parkinson’s disease, schizophrenia, and drug abuse
[1–3]. Dopamine receptors are divided into two subfami-
lies, the Gαs-coupled D1 and D5 receptors and the Gαi/o-
coupled D2,D 3,a n dD 4 dopamine receptors that have stim-
ulatory and inhibitory eﬀects on adenylyl cyclase (AC), res-
pectively (see [3] for a recent review). Acute stimulation
of D2 dopamine receptors leads to inhibition of AC activi-
ty,however,persistentactivation ofthisGαi/o-coupledrecep-
tor paradoxically results in its enhancement [4]. This pheno-
menon, called heterologous sensitization of AC, is also
known as cAMP overshoot, supersensitization, or superacti-
vation of AC. D2 dopamine receptor-induced heterologous
sensitization of cyclic AMP signaling has been demonstrated
in several cellular systems as well as in animal models and
has also been suggested to occur in humans [4–6]. For
example, it was observed that repeated administration of the
D2 receptor agonist quinpirole enhances AC activity in the
caudate putamen, increases CREB phosphorylation, and also
alters behavior in rodents [5, 6]. Although this mode of AC
regulation has been recognized for over three decades [7],
the molecular signaling mechanism causing heterologous
sensitization of AC is only partially understood, attributed to
some extent to diﬀerences in AC isoform-speciﬁc regulation
[4].
There are nine diﬀerentially regulated membrane-bound
AC isoforms in mammalian cells [4, 8]. Whereas all AC
isoforms are stimulated by stimulatory Gαs, only a subset is
inhibited by inhibitory Gαi, and some AC isoforms are dif-
ferentially regulated by Gβγ [4, 8]. Here, we studied human
adenylyl cyclase type 5 (AC5) that is potently stimulated by
Gαs, inhibited by acute activation of Gαi, and conditionally
activated by Gβγ [8] .A C 5i se x p r e s s e da th i g hl e v e l si nt h e
central nervous system and has been identiﬁed as a primary
eﬀector of D2 dopamine receptors in the striatum [9, 10].2 Journal of Signal Transduction
Theaimofthecurrentstudywastoinvestigatetherole(s)
of heterotrimeric G proteins in D2 receptor-mediated het-
erologous sensitization of AC5. By exploring sensitization in
cellsdevoidofendogenousGαs [11],wewereabletoexamine
the ability of Gαs mutants to support sensitization without
interference from endogenous Gαs. Additionally, this Gαs-
deﬁcient cellular model expresses very low levels of AC5
making them a reasonable model for studies of recombinant
AC5 [12]. Heterologous sensitization of AC5 was readily
rescued by wild-type Gαs and by mutants deﬁcient in palmi-
toylation [13]o rG βγ interaction [14]. We also assessed the
role of Gβγ and the signalosome in D2 receptor-induced het-
erologous sensitization of AC5 by sequestering Gβγ subunits
with βARKct-CD8 [15, 16] and coexpressing a dominant-
negative mutant of the Sar1 GTPase [17]. These experiments
revealed that both βARKct-CD8 and Sar1(H79G) attenuated
sensitization,suggestingthatthecomponentsofthesignaling
complex utilized in heterologous sensitization, presumably
AC5 and Gαs, assemble postsynthesis in the endoplasmic
reticulum (ER). Together with previous ﬁndings, the present
data support a model in which Gαs directly interacts with
AC5. In contrast, Gβγ appears to have an indirect role in
heterologous sensitization of AC5.
2.MaterialsandMethods
2.1. Constructs. The human D2L receptor and AC5 or ΔAC5
[18] were cloned into the dual expression vector pBUDCE4
(Invitrogen, Carlsbad, CA) creating pBUD/hAC5, D2Ra n d
pBUD/ΔAC5, D2R. pcDNA3/βARKct-CD8 [15, 16]a n d
pcDNA/vsvg-Sar1 (wild type and H79G) [19]w e r eu s e d .
pcDNA1/Gαs-CFP [20] was a gift from Dr. Catherine Berlot.
The pcDNA3.1/Gαs-IEK+ mutant [21]w a sag i f tf r o mD r .
Philip Wedegaertner. The C3S mutation was created by site-
directed mutagenesis, and the fragment containing the IEK+
mutations was ampliﬁed by PCR. The resulting constructs,
pcDNA1/Gαs-CFP(C3S)andpcDNA1/Gαs-CFP(IEK+)were
sequenced.
2.2. Cell Culture and Transient Transfection. All reagents
were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise noted. Gαs-deﬁcient murine embryonic ﬁbrob-
last cells, GnasE2–/E2– cells [11, 12], were a gift from
Dr. Murat Bastepe. Cells were cultured in 50:50 mix of
F12:DMEM media supplemented with 5% FBS (HyClone,
Logan, UT), 1% Ant-Anti (Invitrogen, Carlsbad, CA) in a
humidiﬁed incubator at 33◦Cw i t h5 %C O 2. Approximately
80,000cells/well were seeded in 24-well plates the day before
transient transfection. DNA (400ng pBUD/hAC5 or ΔAC5,
D2R alone or in combination with 10ng pcDNA/Gαs-
CFP, 300ng pcDNA3/βARKct-CD8, or 300ng pcDNA/vsvg-
Sar1) was mixed with Opti-MEM and 1μL/well Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA). The medium was
replaced with 200μL/well prewarmed Opti-MEM, and the
DNA/Lipofectamine mixture was added to the cells. After
4hr, culture medium (500μL/well) was added, and the cells
were analyzed after 48hr. For microscopy, the amount of
pcDNA/Gαs-CFP was increased to 100ng/well.
2.3. Acute cAMP Accumulation. The assays were carried out
in assay buﬀer (EBSS supplemented with 0.2% ascorbic acid,
15mM HEPES, and 2% BCS (HyClone, Logan, UT), and
500μM IBMX) with 100nM forskolin (Tocris Bioscience,
Ellisville, MO) as noted for 37◦C for 15min. The media was
decanted, ice-cold trichloroacetic acid was added, and the
lysates were stored at 4◦C. Cyclic AMP was quantiﬁed using
a competitive binding assay as described previously [22].
Data were collected from a minimum of three independent
experiments carried out in duplicate and were normalized
to either basal or vehicle conditions. The GraphPad Prism
5 software (GraphPad Software Inc., LaJolla, CA) was used
for data and statistical analyses. A P value of ≤0.05 was
considered statistically signiﬁcant.
2.4. Heterologous Sensitization. The cells were pretreated
with 1μM quinpirole or vehicle in assay buﬀer (without
IBMX) for 2hr followed by three washes. cAMP was measur-
edasdescribedaboveforacutecAMPaccumulation,withthe
additionof1μMspiperonetoblocktheactionofanyresidual
quinpirole.
2.5. Microscopy. Cells were seeded in cover glass slides
(Nunc, Rochester, NY). A 12 bit photometric CoolSNAP
(Roper Scientiﬁc) CCD camera mounted on a TE-2000 in-
verted epiﬂuorescence microscope (Nikon Instruments Inc.,
Melville, NY) with ﬁlters (ex. 500/20, em. 535/30) from
Chroma (Rockingham, VT) was used. Images were acquired
with the MetaMorph software (Molecular Devices, Sunny-
vale, CA) and analyzed using Image J (http://rsbweb.nih
.gov/ij/).
3. Results and Discussion
3.1. Gαs Mutants Rescue Heterologous Sensitization of AC5.
Our laboratory has previously shown that mutants of
canine AC5 that do not interact with Gαs are deﬁcient in
sensitization [23, 24] and that D2-mediated heterologous
sensitization of AC5 has an absolute requirement for Gαs
[12]. Our present objective was to elucidate the mechanism
of Gαs-dependent heterologous sensitization of human AC5
by utilizing two diﬀerent Gαs-CFP [20] mutants (Figure
1(a)).TheC3SsubstitutioneliminatestheN-terminalpalmi-
toylation site, which causes Gαs to mislocalize to the cyto-
solic fraction [13]. The IEK+ mutant contains a series of
substitutions, yielding a Gβγ-binding deﬁcient Gαs that also
displays a reduction in palmitoylation [21].
TheGαs-CFPconstructswerecoexpressedwithAC5 and
D2. Since both C3S and IEK+ are deﬁcient in responses to
receptor stimulation [13, 21], we used direct stimulation
of AC5 with forskolin throughout this study. Basal cAMP
accumulation without any Gαs was 0.73 ± 0.09pmol/ well,
whereasco-expressionofGαs-CFPincreasedcAMPaccumu-
lation to 3.12 ± 0.22pmol/well (wild-type, wt), 4.22 ±
0.06pmol/well (C3S), and 5.88± 0.05pmol/well (IEK+).
Forskolin further stimulated cAMP with values 2.5–3-
fold over basal levels (Figure 1(b)), indicating that wild-
type and both Gαs mutants functionally couple to AC5.Journal of Signal Transduction 3
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Figure 1: Gαs-CFP mutants are functional and rescue heterologous
sensitization of AC5. (a) Schematic of Gαs-CFP constructs. (b)
Acute cAMP accumulation in cells expressing AC5 and D2 alone
(ctrl) or in combination with 10ng Gαs-CFP (wild type, C3S,
or IEK+) was measured under basal (open bars) or forskolin-
stimulated conditions (black bars). ∗∗=P<0.01, ∗= P< 0.05,
using a paired, one-tailed t-test comparing basal and forskolin-
stimulated values. (c) Expression and localization of Gαs-CFP
mutants. (d) Heterologous sensitization of AC5 in cells expressing
AC5 and D2 in the absence or presence of Gαs-CFP. Data
shown represent fold-increase of cAMP accumulation observed in
quinpirole-treated cells. ∗∗=P<0.01, ∗= P< 0.05, using a one-
sample,two-tailedt-testcomparingctrltoeachGαs-CFPconstruct.
Next, expression and subcellular localization of the Gαs-
CFP constructs (in the presence of AC5 and D2)w e r e
evaluated by ﬂuorescence microscopy (Figure 1(c)). Wild-
type Gαs-CFP showed both plasma membrane and intra-
cellular localization, whereas the C3S and IEK+ mutants
were predominantly localized intracellularly (Figure 1(c)),
consistent with previous reports [14, 21].
To assess whether the Gαs-CFP mutants could rescue he-
terologous sensitization, cells were pretreated with vehicle
or quinpirole followed by cAMP accumulation. Consistent
with our previous report [12], no sensitization of AC5 was
observed in the absence of Gαs (Figure 1(d),c t r l ) .I nc o n -
trast, coexpression of wild-type Gαs-CFP resulted in robust
sensitization of AC5 under both basal and forskolin-stim-
ulated conditions (Figure 1(d)). Surprisingly, expression of
the Gαs mutants also signiﬁcantly rescued heterologous sen-
sitization under basal conditions (white bars) and to a less-
er degree forskolin-stimulated conditions (black bars). As
both mutants are deﬁcient in palmitoylation and membrane
localization, neither palmitoylation per se, nor membrane
localization of Gαs appears to be essential for heterologous
sensitization of AC5.
3.2. Role of Gβγ Subunits in Heterologous Sensitization of
AC5. Although we have established that Gαs is required for
heterologous sensitization, our ﬁndings above for the IEK+
mutant suggest that direct interactions between Gαs and
Gβγ a r en o tc r i t i c a l .T h i sp r o m p t e du st of u r t h e ri n v e s t i g a t e
the role of Gβγ in D2 receptor-mediated heterologous
sensitization of AC5. The C-terminus of β-adrenergic kinase
or GRK2 (βARKct) has been used to sequester Gβγ sub-
units and inhibit Gβγ-mediated signaling events, including
heterologous sensitization [15, 25, 26]. In the absence of
βARKct-CD8 (membrane bound βARKct), AC5 displayed
robust heterologous sensitization (open bars, Figure 2(a)).
Sequestering Gβγ blocked sensitization of AC5, under both
basal and forskolin-stimulated conditions, revealing the
necessity of Gβγ for heterologous sensitization of AC5
(black bars, Figure 2(a)). In contrast, βARKct-CD8 had no
substantialeﬀectsonacuteD2 receptoractivation;quinpirole
producedsigniﬁcantinhibitionofcAMPaccumulationinthe
presence of βARKct-CD8 (77 ± 10% inhibition; n = 2, data
not shown). In an eﬀort to explore the site of action for Gβγ-
dependent sensitization, we used an N-terminal deletion
mutant of AC5, ΔAC5. This mutant is functional and
responds to Gαs stimulation but is deﬁcient in binding Gβγ
[18]. The ΔAC5 mutant displayed signiﬁcant sensitization
thatwasalsoblockedbyβARKct-CD8(Figure 2(b)),suggest-
ingthatN-terminalGβγbindingisnotintimatelyinvolvedin
heterologous sensitization of AC5. Instead, there are clearly
additional, unidentiﬁed Gβγ interaction sites in AC5 that are
necessaryforheterologoussensitization.Suchanassumption
is supported by FRET and in vitro activation studies of the
AC5 deletion mutant [18]a sw e l la ss t u d i e so fA C 2 ,w h i c h
possesses multiple motifs for Gβγ interaction and regulation
that are located in the C1b and C2b domains of AC2 [27].
Other possibilities are that ΔAC5 interacts with endogenous
AC isoforms in an AC dimer (see [28]) that binds Gβγ or
that speciﬁc Gβ and Gγ subunits or Gβγ pairs are involved.
However, it is also possible that the Gβγ mechanisms
involving sensitization of AC may be indirect [4].
3.3. Disruption of Signalosome Assembly Aﬀects Heterologous
Sensitization of AC5. Because sequestering Gβγ subunits
alters signalosome assembly [15], we hypothesized that a
speciﬁcsignalingcomplexcouldberequiredforheterologous
sensitization of AC5. Several small GTPases, including Sar1,4 Journal of Signal Transduction
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Figure 2: Sequestration of Gβγ with βARKct-CD8 or coexpression of dominant negative Sar1(H79G) attenuate heterologous sensitization
of AC5. Cells expressing Gαs-CFP, D2R and (a and c) AC5 or (b) ΔAC5 in combination with either empty vector (ctrl), (a-b) βARKct-CD8,
or (c) indicated Sar1 construct. Data shown represent the fold-increase of cAMP accumulation observed in quinpirole-treated cells. (a-b)
∗=P<0.05, using a paired, one-tailed t-test. (c) ∗∗=P<0.01, using a one-way ANOVA and Dunnett’s post hoc test, comparing ctrl to
Sar1(wt) or Sar1(H79G).
are involved in signal complex assembly and anterograde
protein traﬃcking [29]. A series of studies using dominant
negative mutants of these GTPases shows that Gαs and
Gβγ interact with AC2 during traﬃcking to the plasma
membrane [30, 31] and that the Gαs-AC2 interaction is
disrupted by Sar1(H79G) [30].
To study the possibility that interactions between AC5
and its speciﬁc signaling partners play a role, we utilized
Sar1 and Sar1(H79G) and noted that coexpression with the
dominant negative mutant prevented heterologous sensiti-
zation of AC5 (Figure 2(c)). In contrast, acute D2 receptor-
mediated inhibition of AC5 was not signiﬁcantly blocked
in the presence of Sar1(H79G) (data not shown). Our data
are consistent with the ﬁndings that Sar1(H79G) disrupts
AC-Gαs interactions (as measured by BRET or coimmuno-
precipitation) to a larger degree than AC-Gαi interactions
[30]. In contrast, Sar1(H79G) did not aﬀect the interactions
between AC and Gβγ [30], suggesting that the AC interacts
with Gβγ at an early step in the endoplasmic reticulum (ER),
but that the interaction with Gαs occurs after ER export. The
observation that signaling mechanisms of acute activity and
heterologous sensitization are diﬀerentially aﬀected further
supports the hypothesis that heterologous sensitization and
acute stimulation are dependent on separate mechanisms
and possibly separate signalosome components.
4. Conclusion
The present data support a complex model of D2 dopamine
receptor-induced heterologous sensitization of AC5 where
Gαs appears to directly interact with AC5. A role for
Gβγ was conﬁrmed; however, our observations suggest an
indirect role for Gβγ that may be involved during the for-
mation of the sensitization signaling complex. A critical role
for AC5 in mediating dopamine responses has been previ-
ously demonstrated in AC5 deﬁcient mice, which show im-
paired responses to D2 receptor activation [9]. Therefore,
these results have implications in brain regions where D2
dopamine receptors and AC5 are coexpressed, such as the
striatum [32], which is implicated in drug addiction, moti-
vation, mood, and voluntary movement. Persistent D2 dopa-Journal of Signal Transduction 5
mine receptor activation has also been linked to psychiatric
disorders (e.g., schizophrenia and drug abuse) and to the
adaptive responses associated with drug therapy in Par-
kinson’s disease. Enhancing our understanding of the under-
lying components and mechanisms of heterologous sensiti-
zation andregulation of speciﬁcAC activity (in the striatum)
mayaidinthedevelopmentofimprovedandfuturetherapies
for these disorders. For example, recent studies have iden-
tiﬁed small molecule inhibitors of Gβγ-mediated signaling
[33] and AC isoform-speciﬁc inhibitors [34] that may oﬀer
novel therapeutic strategies for modulating complex CNS
behaviors involving dopamine receptor signaling.
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